Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Solola, Taofiq A (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S257000
Reexamination Certificate
active
07998982
ABSTRACT:
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof,wherein R1, R2, and R3, are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
REFERENCES:
patent: 7129235 (2006-10-01), Zheng et al.
patent: 2005/0080095 (2005-04-01), Zheng et al.
patent: 2006/0128755 (2006-06-01), Nakagawa et al.
patent: 1627869 (2006-02-01), None
patent: WO2005004866 (2005-01-01), None
patent: WO 2005004866 (2005-12-01), None
Zcaplus 2005:55064, “Preparation of substituted cyclo (hetero) alkenes for treating pain”, Kyle et. al., Dec. 2005.
Fessenden et. al., Organic Chemistry, 4th Edition, 1990, pp. 156, 815.
Karrer, Org. Chem., 2nd Ed., pp. 92-102 (1946).
Caterina et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor,” Science, 2000, 306-313, vol. 288.
Caterina M.J. et al., “The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway,” (Binary/Image), 1997, 816-824, vol. 389.
Davis et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” (Binary/Image), 2000, 183-187, vol. 405.
Fernihough J., Gentry C., Bevan S., Winter J., “Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis,” Neurosci Lett, 2005, 75-80, 0388-02-01.
Fowler, C. “Intravesical Treatment of Overactive Bladder,” Urology, 2000, 60-64, vol. 55.
Geppetti P., Materazzi S., Nicoletti P., “The transient receptor potential vanilloid 1: role in airway inflmmation and disease,” Eur J Pharmacol, 2006, 207-14, 0533-01-03.
Grennan D.M., Jayson M.I.V., “Rheumatoid arthritis”, Textbook of Pain, 1994, 397-407.
Higuchi T. and Stella V. (Editors). “Pro-Drugs as Novel Delivery Systems,” ACS Symposium Series, 1975, vol. 14.
Hogue J.H., Mersfelder T.L., “Pathophysiology and first-line treatment of osteoarthritis,” Ann Pharmacother, 2002, 679-86, 36/4.
Honore P., Wismer C.T., Mikusa J., et al., “A-425619 [1-lsoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats,” J Pharmacol Exp Thera, 2005, 410-421, 314.
International Search Report for application No. PCT/US08/072560, Mailed on Jan. 29, 2009, 2 pages.
Jia Y., McLeod R.L., Wang X., et al., “Anandamide induces cough in conscious guinea-pigs through VR1 receptors,” Br J Pharmacol, 2002, 0831-06-01, 0137-06-01.
Levine, Ion et.al., “Inflammatory pain,” Textbook of Pain, pp. 45-56.
Marsch R, Foeller E, Rammes G, et al., “Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice,” J Neurosci, 2007, 0832-09-01, 27/4.
McCarthy C., “Osteoarthritis,” Textbook of Pain, pp. 387-396.
Meyer A. Richard et al., “Peripheral neural mechanisms of nociception,” Textbook of Pain, pp. 13-44.
Millan MJ, “The induction of pain: an integrative review,” Prog Neurobiol, 1999, 0164-01-01, 57/1.
Nolano et al., “Topical Capsaicin in Humans: Parallel Loss of Epidermal Nerve Fibers and Pain Sensation,” (Binary/Image), 1999, 135-145, vol. 81.
Prescott, et al., “Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells,” Methods in Cell Biology, 1976, 33-71, vol. 14, Academic Press.
Roche E.B., (Editor). “Bioreversible Carriers in Drug Design,” American Pharmaceutical Association, 1987, Pergamon Press.
Suni A., Szallasi A., “The emerging role of TRPV1 in diabetes and obesity,” Trends in Pharmacology, 2008, 29-36, 29/1.
Szallasi A., Cortright D.N., Blum C.A., et al., “The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept,” Nature Reviews, Drug Discovery, 2007, 357-372, 6.
Tzavara ET, Li DL, Moutsimilli L, et al., “Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdoaminergia-related hyperactivity: therapeutic implications,” Biol Psychiatry, 2006, 508-15, 59/6.
Watanabe N., Horie S., Michael G.J., et al., “Immunohistochemical localization of vanilloid receptor subtype 1 (TRPV1) in the guinea pig respiratory system,” Pulm Pharmacol Ther, 2005, 187-97, 18/3.
Woolf C.J., Decosterd I, “Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients,” Pain, 1999, S141-7, Suppl 6.
Woolf C.J., et al., “Neuronal Plasticity: Increasing the Gain in Pain,” Science, 2000, 1765-1768, 288.
Woolf C.J., Mannion R.J., “Neuropathic pain: aetiology, symptoms, mechanisms, and management,” Lancet, 1999, 1959-1964, 353.
Brown Brian S.
Daanen Jerome F.
Gomtsyan Arthur R.
Jinkerson Tammie K.
Keddy Ryan G.
Abbott Laboratories
Mueller Lisa V.
Polsinelli Shughart PC
Solola Taofiq A
LandOfFree
Amide derivatives as TRPV1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide derivatives as TRPV1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide derivatives as TRPV1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2770990